Palliative care and hospice use among melanoma patients treated with immunotherapy.

116 Background: PD-1/PD-L1 inhibitors (PD-1/PD-L1i) have revolutionized the treatment of patients with metastatic melanoma. However, little is known about the supportive care needs and use of palliative care (PC) services in these patients. We sought to assess rates and correlates of PC consultation and hospice use among melanoma patients treated with PD-1/PD-L1i. Methods: We retrospectively collected data on all patients with melanoma treated with PD-1/PD-L1i at the Massachusetts General Hospital (MGH) from May 2009 to March 2015. We determined rates of PC consultation and hospice use in this sample. We used logistic regression with purposeful selection of covariates to identify correlates of PC consultation. Results: Of 122 patients treated at MGH (mean age = 61.2 years), most were married (n = 91, 75%) and college educated (n = 66, 54%). Overall, 83 patients (68%) experienced autoimmune toxicities, 22 (18%) had liver metastases, 87 (71%) had cancer progression and 44 (36%) died during our study period....